Minerva Neurosciences, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NERV research report →
Range $10 – $10
Price Chart
About the company
Minerva Neurosciences, Inc. functions as a biopharmaceutical firm in the clinical development stage, primarily dedicated to uncovering and bringing to market novel therapeutic options for disorders affecting the central nervous system. Its portfolio of experimental treatments notably features roluperidone, an investigational drug aimed at managing schizophrenia, alongside MIN-301, a soluble recombinant variant of the neuregulin-1b1 protein, which is being explored for its potential in treating Parkinson's disease and various other neurodegenerative conditions.
- CEO
- Remy Luthringer
- IPO
- 2014
- Employees
- 7
- HQ
- Burlington, MA, US
Get TickerSpark's AI analysis on NERV
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $159.80M
- P/E
- -0.12
- Fwd P/E
- 4.43
- PEG
- -0.00
- P/S
- 0.00
- P/B
- -0.79
- EV/EBITDA
- -0.34
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 250.02%
- ROIC
- -38.56%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-15,102,970
- Net Income
- $-293,423,177-20492.7%
- EPS
- $-34.67-18347.4%
- OCF Growth
- -69007.6%
- FCF Growth
- -69007.6%
- 52W High
- $12.46
- 52W Low
- $2.24
- 50D MA
- $4.14
- 200D MA
- $5.05
- Beta
- -0.12
- RSI (14)
- 39
- Avg Volume
- 186.65K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Get the NERV Q1 '23 earnings-call summary
Create a free account to generate an AI summary of this call — key takeaways, results & guidance, CEO/CFO commentary, Q&A, and a bull vs bear read. Ready in about a minute, and it'll be live for everyone.
Create free account →Already have an account? Log in
- Free Float
- 81.5%
- Shares Outstanding
- 46.59M
- Float Shares
- 37.99M
of shares held by institutions
44 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Federated Hermes, Inc. | 4.67M | ▼ 442.80K |
| Jupiter Topco LLC | 4.39M | ▲ 4.39M |
| Vivo Capital, LLC | 4.32M | 0 |
| Janus Henderson Group Ltd. | 4.29M | ▲ 4.29M |
| Balyasny Asset Management L.P. | 4.26M | ▼ 1.60K |
| Logos Global Management LP | 3.29M | ▲ 73.78K |
| Farallon Capital Management LLC | 2.37M | 0 |
| Blackrock, Inc. | 2.24M | ▲ 1.62M |
| Ally Bridge Group (Ny) LLC | 2.18M | ▲ 520.30K |
| Foresite Capital Management Vi LLC | 1.99M | ▼ 1.02K |
| Vanguard Capital Management LLC | 1.89M | ▲ 46.98K |
| Spruce Street Capital LP | 1.66M | 0 |
Held by 76 ETFs
Biggest fund positions in NERV by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 10, 26 | Reilly Joseph H. | other | 0 |
| Aug 10, 26 | Reilly Joseph H. | other | 10,625 |
| Aug 10, 26 | Reilly Joseph H. | other | 22,500 |
| Aug 10, 26 | Reilly Joseph H. | other | 27,000 |
| Aug 10, 26 | Reilly Joseph H. | other | 56,100 |
| Aug 10, 26 | Reilly Joseph H. | other | 47,500 |
| Aug 10, 26 | Reilly Joseph H. | other | 750,000 |
| Aug 10, 26 | Reilly Joseph H. | other | 680,000 |
| Aug 10, 26 | Aliquo Anthony | other | 0 |
| Aug 10, 26 | Aliquo Anthony | other | 5,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our NERV coverage
Recent articles, reports, and earnings notes.
No research on NERV yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NERV report →Minerva Neurosciences to Participate in Two Upcoming Investor Conferences
globenewswire.com · Aug 28
Analysts Set Minerva Neurosciences, Inc (NASDAQ:NERV) Target Price at $10.50
defenseworld.net · Aug 17
Minerva Neurosciences Provides Second Quarter 2026 Financial Results and Business Updates
globenewswire.com · Aug 7
Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs
globenewswire.com · Jun 1
Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs
globenewswire.com · Jun 1
All You Need to Know About Minerva Neurosciences (NERV) Rating Upgrade to Buy
zacks.com · May 20
Minerva Neurosciences (NERV) Loses 37.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
zacks.com · May 20
Minerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare Conference
globenewswire.com · May 18
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.